Page 278 - Drug Class Review
P. 278
Page 169 of 205
Drug Effectiveness Review Project
Authors: Knapp et al., 1994; 68 Farlow et al., 1995; 86 Knopman et al., 1996; 87 Farlow et al., 1998 88
To evaluate the efficacy and safety of high dose TAC over 30 weeks in patients with probable AD
placebo N/A 30 181 Men and women > 50 yrs old with mild to moderate AD and otherwise in good health; met NINCDS Patients with prior exposure to TAC or other analogues; unhealthy patients Medications known to effect the central nervous system and likely to interfere with assessment of efficacy and medications likely to mask the cholinergic side effects of TAC were prohibited; those taking
Alzheimer Drugs Country: US Warner Lambert Study design: RCT Setting: Outpatients at 33 centers Sample size: 653 tacrine 40-80; 40-60-120; 40-80-120-160 6-24; 6-6-18; 6-6-6-12 472 criteria for AD with symptoms of AD for 1 year cimetidine or theophylline were excluded
Final Report Update 1 Adverse Events STUDY: FUNDING: RESEARCH OBJECTIVE: DESIGN: INTERVENTION: Dose (mg/d): Duration (weeks): Sample size: INCLUSION: EXCLUSION: OTHER MEDICATIONS/ INTERVENTIONS ALLOWED: Alzheimer's Drugs
